Glenmark gets USFDA nod

New Delhi: Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic medication to treat psoriatic arthritis in the American market. The company has received final approval from the US Food & Drug Administration (USFDA) for Apremilast tablets in strength of 10 mg, 20 mg and 30 mg, the Mumbai-based drug maker said in a statement. The company’s product is a generic version of Otezla tablets, it added.